Fungal Infections

Microbia Issued Patent For Drug Discovery

Published in TB and Outbreaks Week, December 11th, 2001

The U.S. Patent and Trademark Office has issued a patent protecting methods for regulating fungal gene expression that enable Microbia, Inc.'s, fundamentally new approach to antifungal drug discovery and development.

Specifically, U.S. Patent No. 6,303,302, which has been issued to the Whitehead Institute for Biomedical Research and exclusively licensed to Microbia, includes broad claims to methods of identifying and isolating genes involved in the regulation of fungal gene expression, methods useful for identifying fungal genes that promote infectivity, and methods of identifying agents that regulate the expression or activity of genes required for fungal infection. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry